Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy

被引：15
|
作者：
Ying, Honggang [1 ,2 ,3 ,4 ,5 ]
Xu, Jian [1 ,2 ,3 ,4 ,5 ]
Zhang, Xiaozhen [1 ,2 ,3 ,4 ,5 ]
Liang, Tingbo [1 ,2 ,3 ,4 ,5 ]
Bai, Xueli [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Zhejiang Prov Key Lab Pancreat Dis, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
[3] Zhejiang Prov Innovat Ctr Study Pancreat Dis, Hangzhou 310003, Zhejiang, Peoples R China
[4] Zhejiang Prov Clin Res Ctr Study Hepatobiliary &, Hangzhou 310003, Zhejiang, Peoples R China
[5] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China
来源：
EBIOMEDICINE | 2022年 / 79卷
基金：
中国国家自然科学基金;
关键词：
HHLA2; TMIGD2; KIR3DL3; Immune checkpoint; Cancer immunotherapy; B7; FAMILY-MEMBER; CANCER-IMMUNOTHERAPY; PROGNOSTIC-SIGNIFICANCE; CELL-ADHESION; HHLA2; IDENTIFICATION; EXPRESSION; SURVIVAL; IGPR-1; OVEREXPRESSION;
D O I：
10.1016/j.ebiom.2022.103987
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Human endogenous retrovirus-H long terminal repeat-associating 2 (HHLA2) is a newly emerging immune checkpoint that belongs to B7 family. HHLA2 has a co-stimulatory receptor transmembrane and immunoglobulin domain containing 2 (TMIGD2) and a newly discovered co-inhibitory receptor killer cell Ig-like receptor, three Ig domains, and long cytoplasmic tail (KIR3DL3), which endows it with both immunostimulant and immunosuppression functions in cancer development. In this review, we summarize the HHLA2 expression profile in human cancers, its association with cancer prognosis and clinical features, and its dual roles in regulating cancer immune response through up-to-date literatures. Furthermore, we highlight that precision cancer immunotherapy through manipulating HHLA2-KIR3DL3/TMIGD2 interaction is a promising antitumour strategy.
引用
收藏
页数：11
相关论文
共 34 条
1234